International Lung Cancer Summit shared a post on X:
“Surgeons may be hesitant to recommend neoadjuvant therapy for patients who could have upfront surgery.
At ILCS 2025, Patrick Forde challenged this approach. Data from major phase 3 trials shows that while pCR rates are higher in early stages, the benefit in EFS and OS remains consistent across stage IB/II and III. Stage alone should not dictate the choice between neoadjuvant and adjuvant therapy.
Proceed to the video attached to the post.
More posts about International Lung Cancer Summit.